In Vivo Star Anti-Human HLA class II DR/DQ Antibody
英诺赛图(InnoCyto)的 In Vivo Star Anti-Human HLA class II DR/DQ Antibody(克隆 9.3F10) 为鼠源 IgG2a Kappa 抗体,靶向 Human。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
01产品图片

02产品简介
英诺赛图(InnoCyto)的 In Vivo Star Anti-Human HLA class II DR/DQ Antibody(克隆 9.3F10) 为鼠源 IgG2a Kappa 抗体,靶向 Human。提供 1 mg、5 mg、25 mg 规格,目录价 ¥1,085 起,仅供科研使用(RUO)。
03产品介绍
规格与货号
518901 | 1 mg | ¥1,085
518902 | 5 mg | ¥2,712
518903 | 25 mg | ¥7,458
Product Details
Application|Direct ELISA, functional assay, Flow Cytometry
Target Name|Major Histocompatibility complex II, human leukocyte antigen, HLA, MHC class II
Product Description|In vivo Grade Recombinant Anti-Human HLA class II DR/DQ Monoclonal Antibody
Regulatory Status|RUO
Endotoxin
Storage Conditions|4ºC
Recommended Usage|This product is suitable in in vitro functional assays or in vivo on human cells used in animal models. Optimal amounts need to be determined empirically for each experiment.
See All Formats|Clone 9.3F10
Background Information
HLA-DR and HLA-DQ are members of the major histocompatibility complex (MHC) class II family, which play a central role in orchestrating adaptive immune responses. These molecules are predominantly expressed on professional antigen-presenting cells (APCs), including dendritic cells, macrophages, and B cells, and are responsible for presenting extracellular peptide antigens to CD4⁺ T helper cells. This interaction is essential for initiating immune responses against pathogens, maintaining self-tolerance, and shaping adaptive immunity through cytokine signaling and T cell activation.
Structurally, both HLA-DR and HLA-DQ are heterodimeric glycoproteins composed of an alpha (α) and a beta (β) chain, each anchored in the cell membrane. The α1 and β1 domains form the peptide-binding groove, which accommodates peptides typically 13–25 amino acids in length. Unlike MHC class I, which binds peptides generated from intracellular proteins, class II molecules load peptides derived from extracellular sources. This process occurs in late endosomes or lysosomes, where the invariant chain (Ii) guides and stabilizes the complex until peptide loading occurs via the HLA-DM molecule. Once a stable peptide-MHC complex is formed, it is transported to the cell surface for recognition by the T cell receptor (TCR) on CD4⁺ T cells.
The ligands for HLA-DR and HLA-DQ are peptide antigens derived from pathogens, commensal flora, or self-proteins. The TCR on helper T cells acts as the complementary binding partner, recognizing these peptide–MHC class II complexes with high specificity. Co-stimulatory interactions between APCs and T cells further determine whether the response leads to immune activation or tolerance, making HLA-DR/DQ pivotal in immune regulation.
In disease, specific HLA-DR and HLA-DQ alleles are strongly associated with autoimmune disorders. For instance, HLA-DRB1*03 and DQB1*02 are linked to type 1 diabetes and celiac disease, while HLA-DRB1*04 alleles are associated with rheumatoid arthritis. These genetic variants influence peptide binding preferences and may promote the presentation of self-antigens, triggering autoreactive T cell activation. Moreover, altered HLA-II expression on tumors and infected cells can impair immune surveillance. Elevated HLA-DR expression on immune cells also serves as a marker of immune activation and has been linked to inflammation and chronic infections.
Therapeutically, HLA-DR and HLA-DQ are essential in transplantation compatibility testing, autoimmune disease risk assessment, and antigen-specific immunotherapies. In cancer immunotherapy and vaccine development, understanding an individual’s HLA-II genotype helps tailor peptide-based vaccines and checkpoint inhibitor strategies to optimize T helper cell activation. Likewise, therapies that modulate HLA-II expression or block autoreactive T cell recognition are being explored as treatments for autoimmune diseases such as multiple sclerosis and type 1 diabetes.
Data Sheets
Cat # Size Price Quantity 5189011 mg Add to Cart5189025 mg Add to Cart51890325 mg Add to Cart
04完整参数表
参数由厂商资料整理,采购前请以最终报价单与技术协议为准。
05荣誉与资质
该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。
- 营业执照未上传
- 品牌授权未上传
- 产品检测报告未上传
- 会员身份
- 收费会员
- 经营身份
- 原厂
- 成立年份
- 2020 年
- 所在地
- 上海
- 收录条目
- 1865 个
- 平台核验
- 平台代管
06品牌与供应商
InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。
品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。
07同类条目
同一子类内的条目才具备可比性。跨子类比较参数通常没有意义。
08同品牌其他条目
上海英诺赛图 在本目录共 1865 个条目,除本条外还有:
科研在线(TeleVM). In Vivo Star Anti-Human HLA class II DR/DQ Antibody(518901)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/in-vivo-star-anti-human-hla-class-ii-dr-dq-antibody.html.
TeleVM. (2026, November 12). In Vivo Star Anti-Human HLA class II DR/DQ Antibody(518901). 产品目录. https://www.suprotek.cn/products/item/in-vivo-star-anti-human-hla-class-ii-dr-dq-antibody.html
@misc{biocsp_item_in_vivo_star_anti_human_hla_class_ii_dr_dq_antibody,
title = {In Vivo Star Anti-Human HLA class II DR/DQ Antibody(518901)},
author = {{科研在线}},
year = {2026},
howpublished = {产品目录},
note = {更新于 2026-11-12,产品目录},
url = {https://www.suprotek.cn/products/item/in-vivo-star-anti-human-hla-class-ii-dr-dq-antibody.html}
}
GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。
许可:CC BY-NC 4.0 · 转载注明来源